Zimmer Partners LP purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 252,900 shares of the company's stock, valued at approximately $2,992,000.
Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Roivant Sciences during the fourth quarter worth about $39,000. PNC Financial Services Group Inc. increased its stake in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after acquiring an additional 1,507 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Roivant Sciences by 84.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after purchasing an additional 3,426 shares during the period. Finally, Blue Trust Inc. lifted its stake in shares of Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after purchasing an additional 6,667 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.
Insider Activity
In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $10.95, for a total value of $1,095,000.00. Following the completion of the transaction, the chief operating officer now owns 1,077,197 shares in the company, valued at $11,795,307.15. This represents a 8.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now owns 39,799,611 shares in the company, valued at $456,501,538.17. This represents a 0.68% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,223,959 shares of company stock worth $13,450,035. 7.90% of the stock is currently owned by corporate insiders.
Roivant Sciences Trading Down 0.6%
NASDAQ:ROIV traded down $0.07 during mid-day trading on Monday, hitting $10.87. The company had a trading volume of 2,442,270 shares, compared to its average volume of 5,579,306. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The business has a fifty day simple moving average of $10.53 and a 200-day simple moving average of $11.05. The firm has a market capitalization of $7.76 billion, a price-to-earnings ratio of -72.46 and a beta of 1.23.
Analyst Ratings Changes
A number of analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th.
Get Our Latest Stock Analysis on Roivant Sciences
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Recommended Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
